DMRA Damora Therapeutics, Inc.
Company Analysis
Latest News
🟢 Damora Therapeutics is trading 6.27% up in pre-market
Damora Therapeutics is trading 6.27% up in pre-market at $31.00, versus the September 8 close of $29.17, with no major company-specific announcement dated...
🟢 Damora Therapeutics is trading 5.61% up today
Damora Therapeutics is trading 5.61% up at $29.57, with no clear company-specific catalyst identified for September 4, 2026. - The latest release announced...
🔴 Damora Therapeutics is trading 5% down today as higher oil prices pressure growth equities
Damora Therapeutics is trading 5.03% down at $27.54 amid a broader risk-off session, as higher oil prices, renewed U.S.-Iran tensions, elevated bond yields,...
🔴 Damora Therapeutics is trading 5.49% down today with no clear company-specific catalyst identified
Damora Therapeutics is trading 5.49% down at $28.92, with no clear company-specific announcement or catalyst identified for August 28, 2026. - Its...
🔴 Damora Therapeutics is trading 5% down today as Treasury yields climb
Damora Therapeutics is trading 5.12% down now at $30.78, with broader risk-off conditions the most likely explanation as Treasury yields resumed climbing and...
Damora Therapeutics Lost More Money Than Expected Building Its Blood-Cancer Bet — Can $540 Million in Cash Buy Enough Time?
Shares of Damora Therapeutics (DMRA) cratered 8.6% to $27.00 in pre-market trading after the clinical-stage biotech reported second-quarter results that left...
🔴 Damora Therapeutics is trading 8.6% down in pre-market after quarterly net loss widened to $31.2 million
Damora Therapeutics is trading at $27.00 (-8.6%) after second-quarter results reported on August 10, 2026. • Q2 EPS of -$0.39 beat the -$0.43 consensus...
Damora Therapeutics, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
Damora Therapeutics is expected to report zero revenue and a consensus EPS of -$0.38 for Q2 2026, with the current share price of $29.92 sitting significantly...
Damora Therapeutics, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
Damora Therapeutics is expected to report zero revenue and a consensus EPS loss of $0.38 for Q2 2026, with the stock currently trading at $29.50 compared to a...
🟢 Damora Therapeutics is trading 5.4% up today amid broader market risk-on sentiment
Damora Therapeutics is trading 5.4% higher at $29.86 as a broader market rebound lifts equities despite a lack of company-specific catalysts. • The upward...
Damora Therapeutics Earns Buy Rating, Jefferies Sees 73% Upside in Blood Cancer
Jefferies initiated coverage of Damora Therapeutics (DMRA) on July 27, 2026. Analyst Akash Tewari issued a Buy rating for the stock. The firm set a price...
🟢 Damora Therapeutics is trading 5.1% up today amid risk-on sentiment
Damora Therapeutics is trading 5.1% up at $30.30 today amid a broader market risk-on sentiment, as there are no clear company-specific catalysts for the...
Damora Therapeutics Slumps, Facing Incyte’s Faster and Easier Rival Drug
Damora Therapeutics (DMRA) shares declined on July 22, 2026. Reports indicate a competing blood disorder drug from Incyte will likely reach the market one...
🟢 Damora Therapeutics is trading 5.3% up today after HC Wainwright reiterates Buy rating and $45 price target
Damora Therapeutics is trading 5.3% higher at $34.74 after HC Wainwright reiterated its Buy rating and $45 price target, highlighting significant upside...
🟢 Damora Therapeutics is trading 10.2% up
Damora Therapeutics is trading at $34.68, up 10.2% from a comparison close of $31.48 during regular trading. This is a price-action follow-up, so a separate...
🟢 Damora Therapeutics is trading 5.75% up today on pipeline milestones and strong cash runway
Damora Therapeutics is trading 5.75% up at $33.29 as traders refocus on the company's near-term blood-disorder pipeline milestones and strong cash runway. •...
🟢 Damora Therapeutics is trading 10.1% up
Damora Therapeutics is trading at $30.84, up 10.1% from a comparison close of $28.00 during regular trading. This is a price-action follow-up, so a separate...
🟢 Damora Therapeutics is trading 5.3% up today, rebounding on improved risk sentiment
Damora Therapeutics is trading 5.3% up at $29.49, reversing last week’s pullback amid improving risk sentiment following softer June CPI inflation. • The move...
🔴 Damora Therapeutics is trading 5.1% down today on profit-taking after a recent rally
Damora Therapeutics is trading 5.1% down today at $27.08 on profit-taking and price normalization following a volatile two-week rally. • The reversal comes...
🔴 Damora Therapeutics is trading 5.4% down today after reversing gains from its recent rally
Damora Therapeutics is trading at $29.11 (-5.43%) in a sharp move lower that appears to be a price-action reversal following a 10.8% rise in the prior...